Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate

Udho Thadani, Claude R. Maranda, Ezra A Amsterdam, Leo Spaccavento, Richard G. Friedman, Robert Chernoff, Stephen Zellner, Jeffrey Gorwit, Paul H. Hinderaker

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

■ Objective: To determine whether isosorbide-5-mononitrate (IS-5-MN), an active metabolite of isosorbide dinitrate, when given twice daily (in the morning and 7 hours later), prevents development of tolerance and reduction in exercise performance or is associated with a rebound increase in anginal attacks in patients with stable angina pectoris. ■ Design: Multicenter, placebo-controlled, parallelgroup, double-blind, randomized study. ■ Setting: Four university teaching hospitals and five private cardiology outpatient clinics. ■ Patients: 116 patients with stable exertional angina who stopped treadmill exercise because of angina pectoris. ■ Intervention: After stopping all antianginal drugs with the exception of beta-blockers, patients received singleblind placebo for .1 week followed by either 20 mg of IS-5-MN (n = 60 patients) or placebo (n = 62 patients) twice daily at 0800 hours and 1500 hours for 2 weeks. ■ Measurements: Serial symptom-limited exercise tests and patients' diaries recording activity and date, time, and severity of anginal attacks. ■ Results: Compared with placebo recipients, patients receiving IS-5-MN walked significantly longer at 2, 5, and 7 hours after the 0800-hour dose (P < 0.01) and at 2 and 5 hours after the 1500-hour dose (P < 0.01). Before the morning (0800-hour) dose, exercise duration increased by 0.53 minutes in placebo recipients and by 0.85 minutes in those receiving IS-5-MN therapy (P = 0.10). Neither nocturnal nor early-morning anginal attacks increased during IS-5-MN therapy compared with placebo. Headaches occurred in 19 (32%) patients in the IS-5-MN group and in 9 (15%) patients in the placebo group but necessitated discontinuation of treatment in only 2 (3%) patients in the IS-5-MN group. ■ Conclusion: lsosorbide-5-mononitrate, 20 mg twice daily given 7 hours apart, was well tolerated and improved exercise performance for 7 hours after the morning dose and for 5 hours after the afternoon dose without evidence of development of pharmacologic tolerance. No rebound increase in anginal attacks was found.

Original languageEnglish (US)
Pages (from-to)353-359
Number of pages7
JournalAnnals of Internal Medicine
Volume120
Issue number5
StatePublished - Mar 1 1994

Fingerprint

isosorbide-5-mononitrate
Angina Pectoris
Placebos
Therapeutics
Exercise
Stable Angina
Isosorbide Dinitrate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thadani, U., Maranda, C. R., Amsterdam, E. A., Spaccavento, L., Friedman, R. G., Chernoff, R., ... Hinderaker, P. H. (1994). Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Annals of Internal Medicine, 120(5), 353-359.

Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. / Thadani, Udho; Maranda, Claude R.; Amsterdam, Ezra A; Spaccavento, Leo; Friedman, Richard G.; Chernoff, Robert; Zellner, Stephen; Gorwit, Jeffrey; Hinderaker, Paul H.

In: Annals of Internal Medicine, Vol. 120, No. 5, 01.03.1994, p. 353-359.

Research output: Contribution to journalArticle

Thadani, U, Maranda, CR, Amsterdam, EA, Spaccavento, L, Friedman, RG, Chernoff, R, Zellner, S, Gorwit, J & Hinderaker, PH 1994, 'Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate', Annals of Internal Medicine, vol. 120, no. 5, pp. 353-359.
Thadani, Udho ; Maranda, Claude R. ; Amsterdam, Ezra A ; Spaccavento, Leo ; Friedman, Richard G. ; Chernoff, Robert ; Zellner, Stephen ; Gorwit, Jeffrey ; Hinderaker, Paul H. / Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. In: Annals of Internal Medicine. 1994 ; Vol. 120, No. 5. pp. 353-359.
@article{0193d9d689eb4a6eaf08d584f041cec7,
title = "Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate",
abstract = "■ Objective: To determine whether isosorbide-5-mononitrate (IS-5-MN), an active metabolite of isosorbide dinitrate, when given twice daily (in the morning and 7 hours later), prevents development of tolerance and reduction in exercise performance or is associated with a rebound increase in anginal attacks in patients with stable angina pectoris. ■ Design: Multicenter, placebo-controlled, parallelgroup, double-blind, randomized study. ■ Setting: Four university teaching hospitals and five private cardiology outpatient clinics. ■ Patients: 116 patients with stable exertional angina who stopped treadmill exercise because of angina pectoris. ■ Intervention: After stopping all antianginal drugs with the exception of beta-blockers, patients received singleblind placebo for .1 week followed by either 20 mg of IS-5-MN (n = 60 patients) or placebo (n = 62 patients) twice daily at 0800 hours and 1500 hours for 2 weeks. ■ Measurements: Serial symptom-limited exercise tests and patients' diaries recording activity and date, time, and severity of anginal attacks. ■ Results: Compared with placebo recipients, patients receiving IS-5-MN walked significantly longer at 2, 5, and 7 hours after the 0800-hour dose (P < 0.01) and at 2 and 5 hours after the 1500-hour dose (P < 0.01). Before the morning (0800-hour) dose, exercise duration increased by 0.53 minutes in placebo recipients and by 0.85 minutes in those receiving IS-5-MN therapy (P = 0.10). Neither nocturnal nor early-morning anginal attacks increased during IS-5-MN therapy compared with placebo. Headaches occurred in 19 (32{\%}) patients in the IS-5-MN group and in 9 (15{\%}) patients in the placebo group but necessitated discontinuation of treatment in only 2 (3{\%}) patients in the IS-5-MN group. ■ Conclusion: lsosorbide-5-mononitrate, 20 mg twice daily given 7 hours apart, was well tolerated and improved exercise performance for 7 hours after the morning dose and for 5 hours after the afternoon dose without evidence of development of pharmacologic tolerance. No rebound increase in anginal attacks was found.",
author = "Udho Thadani and Maranda, {Claude R.} and Amsterdam, {Ezra A} and Leo Spaccavento and Friedman, {Richard G.} and Robert Chernoff and Stephen Zellner and Jeffrey Gorwit and Hinderaker, {Paul H.}",
year = "1994",
month = "3",
day = "1",
language = "English (US)",
volume = "120",
pages = "353--359",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate

AU - Thadani, Udho

AU - Maranda, Claude R.

AU - Amsterdam, Ezra A

AU - Spaccavento, Leo

AU - Friedman, Richard G.

AU - Chernoff, Robert

AU - Zellner, Stephen

AU - Gorwit, Jeffrey

AU - Hinderaker, Paul H.

PY - 1994/3/1

Y1 - 1994/3/1

N2 - ■ Objective: To determine whether isosorbide-5-mononitrate (IS-5-MN), an active metabolite of isosorbide dinitrate, when given twice daily (in the morning and 7 hours later), prevents development of tolerance and reduction in exercise performance or is associated with a rebound increase in anginal attacks in patients with stable angina pectoris. ■ Design: Multicenter, placebo-controlled, parallelgroup, double-blind, randomized study. ■ Setting: Four university teaching hospitals and five private cardiology outpatient clinics. ■ Patients: 116 patients with stable exertional angina who stopped treadmill exercise because of angina pectoris. ■ Intervention: After stopping all antianginal drugs with the exception of beta-blockers, patients received singleblind placebo for .1 week followed by either 20 mg of IS-5-MN (n = 60 patients) or placebo (n = 62 patients) twice daily at 0800 hours and 1500 hours for 2 weeks. ■ Measurements: Serial symptom-limited exercise tests and patients' diaries recording activity and date, time, and severity of anginal attacks. ■ Results: Compared with placebo recipients, patients receiving IS-5-MN walked significantly longer at 2, 5, and 7 hours after the 0800-hour dose (P < 0.01) and at 2 and 5 hours after the 1500-hour dose (P < 0.01). Before the morning (0800-hour) dose, exercise duration increased by 0.53 minutes in placebo recipients and by 0.85 minutes in those receiving IS-5-MN therapy (P = 0.10). Neither nocturnal nor early-morning anginal attacks increased during IS-5-MN therapy compared with placebo. Headaches occurred in 19 (32%) patients in the IS-5-MN group and in 9 (15%) patients in the placebo group but necessitated discontinuation of treatment in only 2 (3%) patients in the IS-5-MN group. ■ Conclusion: lsosorbide-5-mononitrate, 20 mg twice daily given 7 hours apart, was well tolerated and improved exercise performance for 7 hours after the morning dose and for 5 hours after the afternoon dose without evidence of development of pharmacologic tolerance. No rebound increase in anginal attacks was found.

AB - ■ Objective: To determine whether isosorbide-5-mononitrate (IS-5-MN), an active metabolite of isosorbide dinitrate, when given twice daily (in the morning and 7 hours later), prevents development of tolerance and reduction in exercise performance or is associated with a rebound increase in anginal attacks in patients with stable angina pectoris. ■ Design: Multicenter, placebo-controlled, parallelgroup, double-blind, randomized study. ■ Setting: Four university teaching hospitals and five private cardiology outpatient clinics. ■ Patients: 116 patients with stable exertional angina who stopped treadmill exercise because of angina pectoris. ■ Intervention: After stopping all antianginal drugs with the exception of beta-blockers, patients received singleblind placebo for .1 week followed by either 20 mg of IS-5-MN (n = 60 patients) or placebo (n = 62 patients) twice daily at 0800 hours and 1500 hours for 2 weeks. ■ Measurements: Serial symptom-limited exercise tests and patients' diaries recording activity and date, time, and severity of anginal attacks. ■ Results: Compared with placebo recipients, patients receiving IS-5-MN walked significantly longer at 2, 5, and 7 hours after the 0800-hour dose (P < 0.01) and at 2 and 5 hours after the 1500-hour dose (P < 0.01). Before the morning (0800-hour) dose, exercise duration increased by 0.53 minutes in placebo recipients and by 0.85 minutes in those receiving IS-5-MN therapy (P = 0.10). Neither nocturnal nor early-morning anginal attacks increased during IS-5-MN therapy compared with placebo. Headaches occurred in 19 (32%) patients in the IS-5-MN group and in 9 (15%) patients in the placebo group but necessitated discontinuation of treatment in only 2 (3%) patients in the IS-5-MN group. ■ Conclusion: lsosorbide-5-mononitrate, 20 mg twice daily given 7 hours apart, was well tolerated and improved exercise performance for 7 hours after the morning dose and for 5 hours after the afternoon dose without evidence of development of pharmacologic tolerance. No rebound increase in anginal attacks was found.

UR - http://www.scopus.com/inward/record.url?scp=0028097946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028097946&partnerID=8YFLogxK

M3 - Article

C2 - 8093132

AN - SCOPUS:0028097946

VL - 120

SP - 353

EP - 359

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -